Merck shakes hands with Acceleron; Finally, a pill for Covid-19; The past and future of contract research; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
You may remember from the beginning of this year that Endpoints News’ 2021 plan is to go broader and deeper. As part of that effort, we will be launching a new weekly newsletter — Endpoints Marketing Rx — to cover all things pharma marketing. You can sign up the same way some of you signed up for this report: by visiting your reader profile.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.